{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:13:03Z","timestamp":1793167983259,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clinre.2024.102357","type":"journal-article","created":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T14:23:29Z","timestamp":1714314209000},"page":"102357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of aldafermin in non-alcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1572-0740","authenticated-orcid":false,"given":"Mohamed Mahmoud","family":"Marey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Belal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelaziz A.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eslam Mohammed","family":"Rabea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malak A.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed W.","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4845-4119","authenticated-orcid":false,"given":"Abdulqadir J.","family":"Nashwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl","key":"10.1016\/j.clinre.2024.102357_bib0001","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of non-alcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2024.102357_bib0002","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10198-020-01256-y","article-title":"Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018","volume":"22","author":"Morgan","year":"2021","journal-title":"Eur J Health Econ"},{"issue":"3","key":"10.1016\/j.clinre.2024.102357_bib0003","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1053\/j.gastro.2021.04.074","article-title":"Preparing for the NASH epidemic: a call to action","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.clinre.2024.102357_bib0004","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of non-alcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.clinre.2024.102357_bib0005","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41392-022-01119-3","article-title":"Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver\/steatohepatitis (NAFL\/NASH)","volume":"7","author":"Xu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.clinre.2024.102357_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101152","article-title":"FGF19 and FGF21: in NASH we trust","volume":"46","author":"Talukdar","year":"2021","journal-title":"Mol Metab"},{"issue":"6","key":"10.1016\/j.clinre.2024.102357_bib0007","doi-asserted-by":"crossref","first-page":"e67160","DOI":"10.1371\/journal.pone.0067160","article-title":"Association between serum atypical fibroblast growth factors 21 and 19 and pediatric non-alcoholic fatty liver disease","volume":"8","author":"Alisi","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.clinre.2024.102357_bib0008","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/cts.12839","article-title":"Evolving role for pharmacotherapy in NAFLD\/NASH","volume":"14","author":"Attia","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"1","key":"10.1016\/j.clinre.2024.102357_bib0009","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with non-alcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2024.102357_bib0010","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. [cited 2024 Jan 2]. Available from: https:\/\/training.cochrane.org\/handbook\/current."},{"key":"10.1016\/j.clinre.2024.102357_bib0011","volume":"372","author":"Page","year":"2021"},{"issue":"1","key":"10.1016\/j.clinre.2024.102357_bib0012","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014A web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.clinre.2024.102357_bib0013","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.clinre.2024.102357_bib0014","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/HEP.0000000000000607","article-title":"A randomized, double-blind, placebo-controlled trial of Aldafermin in patients with non-alcoholic steatohepatitis and compensated cirrhosis","volume":"79","author":"Rinella","year":"2024","journal-title":"Hepatology"},{"issue":"10126","key":"10.1016\/j.clinre.2024.102357_bib0015","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomized, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.clinre.2024.102357_bib0016","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S2468-1253(22)00017-6","article-title":"Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): a randomized, double-blind, placebo-controlled, phase 2b trial","volume":"7","author":"Harrison","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.clinre.2024.102357_bib0017","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American association of clinical endocrinology clinical practice guideline for the diagnosis and management of non-alcoholic fatty liver disease in primary care and endocrinology clinical settings","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"7","key":"10.1016\/j.clinre.2024.102357_bib0018","first-page":"371","article-title":"Update on clinical trials for non-alcoholic steatohepatitis","volume":"19","author":"Nathani","year":"2023","journal-title":"Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.clinre.2024.102357_bib0019","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of non-alcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.clinre.2024.102357_bib0020","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.clinre.2024.102357_bib0021","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.jceh.2022.01.011","article-title":"Pharmacotherapeutic impact on non-alcoholic steatohepatitis histology: a systematic review and network meta-analysis","volume":"12","author":"Kovalic","year":"2022","journal-title":"J Clin Exp Hepatol"},{"issue":"10","key":"10.1016\/j.clinre.2024.102357_bib0022","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/j.numecd.2022.07.001","article-title":"Effect of pharmacological interventions and placebo on liver Histology in non-alcoholic steatohepatitis: a network meta-analysis","volume":"32","author":"Pennisi","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"4","key":"10.1016\/j.clinre.2024.102357_bib0023","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/hep.30782","article-title":"Report on the AASLD\/EASL joint workshop on clinical trial endpoints in NAFLD","volume":"70","author":"Rinella","year":"2019","journal-title":"Hepatology."},{"issue":"7","key":"10.1016\/j.clinre.2024.102357_bib0024","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.clinre.2024.102357_bib0025","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of fibrosis development in non-alcoholic steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"issue":"37","key":"10.1016\/j.clinre.2024.102357_bib0026","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.3748\/wjg.v29.i37.5327","article-title":"Efficacy and safety of semaglutide in non-alcoholic fatty liver disease","volume":"29","author":"Zhu","year":"2023","journal-title":"World J Gastroenterol"},{"issue":"10215","key":"10.1016\/j.clinre.2024.102357_bib0027","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomized, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.clinre.2024.102357_bib0028","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clinre.2024.102357_bib0029","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.16583","article-title":"Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH","volume":"54","author":"Majzoub","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.clinre.2024.102357_bib0030","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for non-alcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2024.102357_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2023.117461","article-title":"Analytical performance of the enhanced liver fibrosis (ELF) test on the Atellica IM analyzer","volume":"548","author":"Palladino","year":"2023","journal-title":"Clin Chim Acta"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740124000780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740124000780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T15:56:35Z","timestamp":1717343795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740124000780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2210740124000780"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2024.102357","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of aldafermin in non-alcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2024.102357","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102357"}}